While issues surrounding gender equality in the workplace have become more prominent than before, women continue to face a myriad of challenges in the workplace and particularly at the senior leadership level. At the 5th Women in Leadership Forum, we will focus on unleashing the power of female leaders across business, government, academia, and sports in China and around the world.
Focusing on empowering women at senior levels, the Women in Leadership Forum has become a flagship event jointly held since 2013 by the Cheung Kong Graduate School of Business (CKGSB) and United Nations Entity for Gender Equality and the Empowerment of Women (UN WOMEN).
As a platform for empowering female leaders, promoting gender equality in the workplace, celebrating success stories, and offering opportunities to create positive change, the Women in Leadership Forum offers unique insights from distinguished leaders like Sheryl Sandberg (Facebook’s COO), Barbara Woodward (British Ambassador to China), Jan Adams (Former Australian Ambassador to China) and Jean Liu (President of Didi Chuxing Technology Co), among many others.
CKGSB MBA Program and Embassy of Israel in China are going to co-host the “Meet the Counselor” event on January 8th, 2020 from 18：30-20：15 at CKGSB Beijing Campus. Mr. Erez Katz Volovelsky, Counselor, Spokesperson, Director of Communication & Public Diplomacy of Embassy of Israel, will deliver a keynote speech, decoding the ecosystem of Israel innovation.
“Meet the Counselor” is the flagship event series in 2020. CKGSB MBA Program will co-host a series of events with counsellors from different countries, starting from Israel. Please click here to register for the opening event of “Meet the counselor” series.
China’s healthcare market is experiencing double-digit growth, but the relatively low healthcare spending as a portion of GDP suggests that there’s still room to grow. In the pharmaceutical sector, specifically, China was the world’s second-largest national pharmaceutical market in 2017 — worth $122.6 billion, according to CNBC. But, as China’s aging population puts pressure on the public health system, the government has identified the healthcare industry as an area in need of reform.
Multinational pharmaceutical companies have benefited in China from selling off-patent branded drugs at a premium price and Chinese pharmaceutical companies happily sold low-cost generic drugs with gross margins of 80-90 percent. In a recent shake-up, China rolled out the “4+7” bulk-buying policy in an effort to drive down prices of generic drugs and force local players to become more globally competitive by investing in more R&D.
What does the new policy mean for established multinational pharmaceutical companies who have benefited from a decentralized system of quality control? How will Chinese pharmaceutical companies balance out the loss of revenue from the fall in generic drug prices? And what does the shifting landscape mean for new players hoping to gain a slice in this lucrative market? Professor of Finance Li Haitao explains.
Co-organizer: Foreign Correspondents’ Club of China (FCCC)
Fee: RMB 100
Stock markets on both sides of the Pacific have been volatile amidst mounting trade war tensions and rising tariffs. Chinese stock markets in particular have performed badly last year. Cheung Kong Graduate School of Business Professor of Accounting and Finance Liu Jing will explain how investors and finance professionals view the importance of China’s A-shares, and analyze the market sentiment given the actual value and performance in the first quarter of 2019, based on his most recent survey.
CKGSB Alumni/Students RSVP: please email xftian@ckgsb.edu.cn
non-CKGSB-alumni/students RSVP: Please register via this link www.fccchina.org/events/20190529/
FEE: FCCC members free, non-members 100 RMB
